Chelate ligand compound, derivative, preparation method of chelate ligand compound, conjugate formed by chelate ligand compound and derivative, and application of conjugate

By designing a new chelating ligand compound with chelating groups and connecting arms of multiple nitrogen atoms, the problems of metal nuclide stability and high temperature labeling in the prior art are solved, and stable chelation with large atomic radius and multi-charged metal ions are achieved, and the stability and targeting of radiopharmaceuticals are improved.

CN120230058APending Publication Date: 2025-07-01NANJING THERANOSTA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311855884.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-12-29
Publication Date
2025-07-01

AI Technical Summary

Technical Problem

The existing chelating ligand compounds cannot be stably complexed with metal nuclides with larger ionic radius and more free charges, resulting in metal chelates being instable in vivo, limiting their application in medical diagnosis and treatment, while high temperature labeling processes may destroy the structural integrity of the targeted portion.

Method used

A new chelating ligand compound, chelating groups and linking arms containing multiple nitrogen atoms, was developed, able to chelate with metal nuclides at room temperature, forming stable metal complexes, and connecting to target molecules through different terminal groups, improving targeting and biological properties.

Benefits of technology

Stable chelation with a variety of metal ions, especially large atomic radius and multi-charged metal ions, is achieved, which improves the in vitro stability and purity of radioactive drugs, simplifies the labeling process, and enhances the targeted diagnostic and therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120230058A_ABST
    Figure CN120230058A_ABST
Patent Text Reader

Abstract

The invention relates to a chelating ligand compound, a derivative, a preparation method of the chelating ligand compound, a conjugate formed by the chelating ligand compound and the derivative and application of the conjugate. The chelating ligand compound disclosed by the invention has larger chelating space and chelating capacity, and can form a stable structure with various metal ions, especially metal ions with large atomic radius and more charges, so that the chelating ligand compound has higher in-vitro stability, and provides more possibilities for radiopharmaceutical treatment. Moreover, the chelating ligand compound disclosed by the invention has a large skeleton, so that high-temperature heating is not needed in the metal nuclide process, the possibility that the skeleton structure is damaged in the heating process is avoided, meanwhile, the metal nuclide labeling process is simple and fast, and the radiochemical purity of the final target radiopharmaceutical is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the research field of chelating ligand compounds capable of chelating metal ions, especially radionuclides, and specifically relates to a chelating ligand compound, derivatives thereof, a preparation method thereof, a conjugate formed thereby, and applications thereof. Background Art

[0002] Radioactive chelates or targeting compounds with radioactive labels have been widely used in diagnostics, which generally need to include at least several parts such as a chelating ligand for complexing radionuclides, a linker, and a targeting molecule or crosslinking group.

[0003] Currently, more and more metal radionuclides are being developed to become new theranostic metals. However, due to their relatively large ionic radii and relatively large charges, the known chelating ligands in the prior art cannot stably complex with them, resulting in the formed metal chelates being unable to maintain sufficient stability in the body, and thus a series of side effects are expected to occur, which limits the application of these metal radionuclides in medicine, especially diagnostic medicine.

[0004] Meanwhile, for existing relatively mature chelating ligand compounds, such as traditional DOTA and DTPA ligands, high-temperature conditions are required during the labeling process of some large-molecular-weight radionuclides, and such high-temperature conditions may damage the structural integrity of the antibody targeting part, which also makes traditional ligands unable to meet the chelating requirements of more metal radionuclides.

[0005] Therefore, for those skilled in the art, developing new chelating ligand compounds that can meet the chelating requirements of more metal radionuclides, especially those with relatively large ionic radii and relatively large free charges, has become a hot and difficult point in the research and development of those skilled in the art. Summary of the Invention

[0006] One of the invention objects of the present invention is to provide a new chelating ligand compound, in which the chelating group in the chelating ligand compound can achieve chelation with metal radionuclides having relatively large ionic radii and relatively large free charges. Thus, after connecting a targeting molecule on this basis, the conjugate formed can further chelate metal radionuclides and have better targeting properties and biological properties.

[0007] Meanwhile, the present invention also provides a preparation method of the above-mentioned chelating ligand compound and its derivatives, and their applications in the preparation of radioactive drugs. The radioactive drugs can be used for the diagnosis and treatment of related diseases.

[0008] To achieve the above invention object, the present invention provides a new chelating ligand compound, the chelating ligand compound includes a chelating group containing multiple nitrogen atoms and at least one linker connected to the nitrogen atom on the chelating group:

[0009]

[0010] Wherein:

[0011] Z is a chelating group containing multiple nitrogen atoms and has the following structure:

[0012]

[0013] R1 and R2 are substituents on the benzene ring, and the substituent does not contain residues reactive with the target molecule; further preferably, R1 = R2; more preferably, both R1 and R2 are methyl groups;

[0014] K is an alkyl chain containing heteroatoms O, S, P or N and is connected by several R k connected through a heteroatom or a heteroatom-containing group, wherein R k is independently and arbitrarily selected from substituted or unsubstituted alkyl groups;

[0015] L is a linker arm portion connected to the N atom in the chelating group Z, and the linker arm portion L has a terminal group X for connecting to the target molecule or the targeting group.

[0016] The terminal group X on the linker arm portion L is an important part for connecting to the target molecule or the targeting group. According to the connection requirements of different target molecules or targeting groups, different terminal groups X can be connected, so that the connection with the target molecule can be achieved through covalent bond connection, ligand connection or through hydrophobic bond and electrostatic interaction, etc.

[0017] The other end of the linker arm portion L is connected to the nitrogen atom of the chelating group Z, thereby forming a chelating ligand compound capable of coupling with different target molecules or targeting groups.

[0018] Sometimes we may need several identical or different terminal groups X. These terminal groups X can be designed on one linker arm portion L or on different linker arm portions L. The specific design ideas and methods can refer to the connection methods of the targeting molecule or the targeting group with the linker arm portion L in the prior art.

[0019] When K is an alkyl chain containing heteroatoms O, S, P, the linker arm portion L is connected to one, or two, or three, or four of the four nitrogen atoms on the chelating group Z; when K is an alkyl chain containing heteroatom N, the N atom on the K chain can also be connected to the linker arm portion L, which provides more connection sites for the linker arm portion L. Of course, this does not mean that all nitrogen atoms need to be connected to the linker arm portion L, as long as at least one nitrogen atom is connected to the linker arm portion L.

[0020] When both R1 and R2 are in the para-position of the hydroxyl group, at this time, except for the possible nitrogen atoms on the alkyl chain K, the other four nitrogen atoms have the same environment. When K is an alkyl chain containing a heteroatom N, the nitrogen atom on the alkyl chain K and the other nitrogen atoms are not completely equivalent due to their positions, and at this time, two nitrogen atoms in different environments are formed.

[0021] As a further preferred technical solution, the linking arm part L is selected from groups having the following formula:

[0022] L m -X

[0023] Wherein:

[0024] X is —COOH, —OH, —CO, —SH, —CO—N(CH3)OH, —NH2, —H2PO3, —H2PO4, —H2PO2 or a halogen;

[0025] L m is a substituted or unsubstituted alkyl group. Preferably, L m is a substituted or unsubstituted C0-C3 alkyl group.

[0026] Further preferably, the chelating ligand compound further includes a group Q, and the group Q is a heteroatom group with a lone pair of electrons;

[0027] There are two ways of connecting the group Q to the chelating group Z,

[0028] One is that the group Q is connected between the chelating group Z and the linking arm part L,

[0029]

[0030] The other is that the group Q is directly connected to the N atoms in the chelating group Z that are not connected to the linking arm part L,

[0031]

[0032] It should be known that two ways of connecting the group Q to the chelating group Z are provided here, but it does not mean that in a specific embodiment, the group Q can only adopt one of the two mutually exclusive connection methods. On the contrary, in a technical solution, for the group Q, there may be two different ways of connecting to the chelating group Z at the same time, and these groups Q can be the same or different.

[0033] Further preferably, the group Q is selected from groups having the following formula,

[0034] Q m -X Q ;

[0035] Wherein:

[0036] Q m is a substituted or unsubstituted alkyl group, preferably, Q m is a substituted or unsubstituted C0-C3 alkyl group;

[0037] X Q is a heteroatom group with a lone pair of electrons, including but not limited to —COOH, —H2PO3, —H2PO4 or —H2PO2.

[0038] Furthermore, the present invention also discloses that R k is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl, and these Rk are connected through a heteroatom to form an alkyl chain K containing two or three R k groups.

[0039] More preferably, in the present invention, it is further disclosed that the alkyl chain K containing heteroatoms O, S, P or N in the chelating ligand compound is selected from:

[0040]

[0041] any one of them.

[0042] Meanwhile, in the present invention, it is further preferably disclosed that the chelating ligand compound is selected from:

[0043]

[0044]

[0045] any one of them.

[0046] Furthermore, the present invention also discloses derivatives of the chelating ligand, and the derivatives are compounds having the structure shown by the following formula or salts formed by them with inorganic acids or organic acids,

[0047]

[0048] In this formula, the definition of K is as described above, that is, K is an alkyl chain containing heteroatoms O, S, P or N, which is formed by connecting several R k through heteroatoms or heteroatom-containing groups, wherein R k independently and arbitrarily is selected from substituted or unsubstituted alkyl groups; and preferably R k is selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, substituted or unsubstituted propyl, and these Rk are connected through a heteroatom to form an alkyl chain containing two or three Rk the alkyl chain K; meanwhile, K is further preferably any one of the following formulas:

[0049]

[0050] Furthermore, the present invention also discloses a conjugate formed after the chelating ligand compound is conjugated with a target molecule or a targeting group. As described above, the target molecule or the targeting group is conjugated through the terminal group X of the linker moiety L.

[0051] The target molecule can be selected from biomacromolecules, or can be selected from drugs or small molecule compounds. The target molecule and the targeting group include but are not limited to antibodies, proteins, peptides, carbohydrates, nucleotides, oligonucleotides, oligosaccharides, vitamins, liposomes, small molecule drugs or fragments or derivatives, etc.

[0052] Furthermore, in the present invention, a preparation method of the chelating ligand compound is also provided. This method is prepared from substituted or unsubstituted 2,6-diformylphenol and NH2—K—NH2, where the definition of K is as described above.

[0053] In the present invention, a metal complex is also disclosed. The metal complex is formed by complexing the aforementioned chelating ligand compound or conjugate with a metal element.

[0054] And furthermore, the present invention also discloses the application of the aforementioned chelating ligand compound, the derivative, the conjugate, and the metal complex in the preparation of radiopharmaceuticals. The radiopharmaceuticals prepared by compounds formed by combining different target molecules and different radionuclides can be used for targeted diagnosis and treatment of different diseases.

[0055] The application of the metal complex in radiopharmaceuticals is disclosed in the present invention. In this application, the metal is a metal radionuclide, where the radionuclide can be 89 Zr, 47 Sc, 55 Co, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 67 Cu, 66 Ga, 67 Ga, 68 Ga, 82 Rb, 86 Y, 87 Y, 90 Y, 97 Ru, 105 Rh, 109 Pd, 111 In, 117m Sn,149 Pm, 52 Mn, 149 Tb, 152 Tb, 153 Sm, 177 Lu, 186 Re, 188 Re, 199 Au, 201 Tl, 203 Pb, 212 Pb, 212 Bi, 213 Bi, 225 Ac, 223 Ra and 227 Th, etc., among which the chelating ligand compounds disclosed in the present invention have particularly significant advantages in chelating lanthanide elements and actinide elements. For example, 68 Ga used in the examples of the present invention.

[0056] The chelating ligand compounds disclosed in the present invention have a larger chelating space and chelating ability, and can form stable structures with a variety of metal ions, especially metal ions with a large atomic radius and a large charge, thereby having higher in vitro stability, providing more possibilities for radiopharmaceutical therapy. Moreover, due to the large skeleton of the chelating ligand compounds disclosed in the present invention, when combined with radionuclides, high-temperature heating is not required, which avoids the possibility of the skeleton structure being damaged during the heating process. At the same time, it also makes the process of radionuclide labeling simple and fast, improving the radiochemical purity of the final target radiopharmaceutical. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] Figure 1 Schematic diagram of the single crystal structure of Compound 2 obtained in Example 1.

[0058] Figure 2 Schematic diagram of the single crystal structure of the target chelating ligand compound R1 obtained in Example 1.

[0059] Figure 3 For Compound 2 obtained in Example 1 1 HNMR spectrum.

[0060] Figure 4 For Compound 3 obtained in Example 1 1 HNMR spectrum.

[0061] Figure 5 For Compound 11 obtained in Example 7 1 HNMR spectrum.

[0062] Figure 6 For Compound R4 obtained in Example 7 1HNMR spectrum.

[0063] Figure 7 HNMR spectrum of compound R6 obtained in Example 9. 1 HNMR spectrum.

[0064] Figure 8 For the compound in Example 14 68 Schematic diagram of the thin-layer chromatography detection result of Ga-R1.

[0065] Figure 9 For the compound in Example 14 68 Schematic diagram of the thin-layer chromatography detection result of Ga-R2.

[0066] Figure 10 For the compound in Example 14 68 Schematic diagram of the thin-layer chromatography detection result of Ga-R3.

[0067] Figure 11 For the compound in Example 14 68 Schematic diagram of the thin-layer chromatography detection result of Ga-R4.

[0068] Figure 12 For the compound in Example 14 68 Schematic diagram of the thin-layer chromatography detection result of Ga-R5.

[0069] Figure 13 For the compound in Example 14 68 Schematic diagram of the thin-layer chromatography detection result of Ga-R6.

[0070] Figure 14 For the compound in Example 15 68 Schematic diagram of the high-performance liquid chromatography analysis result of Ga-R1-4.

[0071] Figure 15 For the compound in Example 15 68 Schematic diagram of the high-performance liquid chromatography analysis result of Ga-R1-5.

[0072] Figure 16 For the compound in Example 15 68 Schematic diagram of the high-performance liquid chromatography analysis result of Ga-R1-6.

[0073] Figure 17 For the compound in Example 15 68 Schematic diagram of the high-performance liquid chromatography analysis result of Ga-R1-7.

[0074] Figure 18 For the compound in Example 15 68 Schematic diagram of the high-performance liquid chromatography analysis result of Ga-R1-10.

[0075] Figure 19 For the compound in Example 15 68 Schematic diagram of the high performance liquid chromatography analysis result of Ga-R1-11.

[0076] Figure 20 For the compound in Example 15 68 Schematic diagram of the high performance liquid chromatography analysis result of Ga-R1-12.

[0077] Figure 21 For the injected compound in Example 16 68 PET scan image of nude mice injected with Ga-R1-4.

[0078] Figure 22 For the injected compound in Example 16 68 PET scan image of nude mice injected with Ga-R1-6.

[0079] Figure 23 For the injected compound in Example 16 68 PET scan image of nude mice injected with Ga-R1-12.

[0080] Figure 24 For Example 17 68 Schematic diagram of the distribution result of Ga-R1-4 in tumor-bearing mice. Detailed implementation mode

[0081] To better understand the present invention, the following further elaborates the present invention in combination with specific examples.

[0082] The reagents and instruments not specifically described or noted in the examples are all commercially available conventional products and can be obtained by purchase. The conditions not specifically described or noted can all be carried out according to the conventional conditions in the art or the conditions in the instruction manual of the relevant product seller.

[0083] The present invention is prepared from substituted or unsubstituted 2,6-diformylphenol and NH2—K—NH2. Specifically, substituted or unsubstituted 2,6-diformylphenol and NH2—K—NH2 are mixed and reacted to obtain a macrocyclic compound (Schiff base), which is reduced with sodium borohydride and then reacted with tert-butyl bromoacetate (or hydroxylamine intermediate or phosphate intermediate), and the obtained intermediate is hydrolyzed to generate the target compound.

[0084] Example 1

[0085]

[0086] Dissolve 2,6-diformyl-4-methylphenol (1.225 g, 7.4 mmol) in 30 ml DMF solution and heat to 90°C. Add 2,2′-(ethylenedioxy)bis(ethylamine) (1.10 g, 7.4 mmol) in 30 ml DMF solution dropwise at 90°C. Continue the reaction for 2 hours after the dropwise addition is complete. Then concentrate the reaction solution to obtain compound 1.

[0087] Sodium borohydride (0.562 g, 14.8 mmol) was added to the methanol solution of compound 1 under stirring, and the mixture was stirred for 1 hour. The solvent was removed under reduced pressure, and the residue was extracted and washed with ethyl acetate / water, and dried over anhydrous sodium sulfate. The mixture was filtered, and 10 ml of hydrogen chloride dioxane solution (4 M) was added to the filtrate. The precipitated solid was filtered and dried to obtain the hydrochloride of compound 2 (2.6 g).

[0088] LC-MS: 561.4(M+1), 281.2(M / 2+1)

[0089] H-NMR (300M, D2O): δ2.28 (s, 6H), 3.31-3.33 (t, 8H), 3.77 (s, 8H), 3.85-3.87 (t, 8H), 4.29 (s, 8H), 7.28 (s, 4H), see for specific spectra Figure 3 .

[0090] Weigh 100 mg of compound 2 and dissolve it in 2 ml of methanol. Filter and add 4 ml of ether to the filtrate. Cover and let stand for 3 weeks. Single crystals will grow. Figure 1 shown.

[0091] The hydrochloride of compound 2 (600 mg, 0.85 mmol), tert-butyl bromoacetate (623 mg, 3.2 mmol), DIEA (1.4 g, 10.8 mmol) and 30 ml of acetonitrile were mixed and reacted at room temperature for 2 hours. The mixture was concentrated to dryness, extracted with ethyl acetate / water, dried and concentrated to obtain a crude product, and purified to obtain compound 3 (788 mg).

[0092] LC-MS: 509.3 (M / 2+1).

[0093] Compound 3 (788 mg, 0.775 mmol) was dissolved in 4M hydrochloric acid (3 ml) and reacted at 45°C for 0.5 hours. The mixture was concentrated to dryness under reduced pressure to obtain the target compound R1 (594 mg). For the specific spectrum, see Figure 4 .

[0094] LC-MS: 793.4(M+1), 397.2(M / 2+1)

[0095] 1H-NMR (300 MHz, D2O): δ 2.26 (s, 6H), 3.56 - 3.58 (t, 8H), 3.75 (s, 8H), 3.94 - 3.96 (t, 8H), 4.03 (s, 8H), 4.52 (br, 8H), 7.32 (s, 4H)

[0096] Weigh 10 mg of compound R1 and dissolve it in 1 ml of MeOH (ultra-dry, filtered); add 232 μl of 0.024 M Cu(NO3)2 / MeOH solution. Add 840 μl of 0.1 M NaOH / MeOH solution, and the color of the whole solution turns dark green. Filter, add 4 ml of diethyl ether, cover and let stand for 2 weeks to grow single crystals, and the structure is as Figure 2 shown.

[0097] Example 2

[0098] In this example, we prepared compounds R1-1, R1-2, R1-3, R1-4, R1-5, and R1-6 by coupling compound R1 with compound W.

[0099]

[0100] Dissolve compound 4 (79.2 mg, 0.1 mmol), N,N-diisopropylethylamine (64.5 mg, 0.5 mmol), and HATU (152 mg, 0.4 mmol) in 2 ml of DMF solution. After stirring for 10 min, add compound W (146 mg, 0.3 mmol). After reacting for 6 h, concentrate the reaction solution under reduced pressure, and use preparative liquid chromatography to purify and separate the compounds:

[0101] R1-1 (21.3 mg), LC-MS: 631.3 (M / 2 + 1)

[0102] R1-2 (0.2 mg), LC-MS: 577.3 (M / 3 + 1)

[0103] R1-3 (0.3 mg), LC-MS: 577.3 (M / 3 + 1)

[0104] R1-4 (29.1 mg), LC-MS: 577.3 (M / 3 + 1)

[0105] R1-5 (39.4 mg), LC-MS: 733.6 (M / 3 + 1), 550.5 (M / 4 + 1)

[0106] R1-6 (6.9 mg), LC-MS: 667.5 (M / 4 + 1), 534.2 (M / 5 + 1)

[0107]

[0108]

[0109] Example 3

[0110] In this example, we prepared compounds R1-7, R1-8, R1-9, R1-10, R1-11, and R1-12 by coupling compound R1 with compound X.

[0111]

[0112] Dissolve compound R1 (79.2 mg, 0.1 mmol), N,N-diisopropylethylamine (64.5 mg, 0.5 mmol), and HATU (152 mg, 4 mmol) in 2 ml of DMF solution. After stirring for 10 min, add compound X (250 mg, 3 mmol). After reacting for 2 h, concentrate the reaction solution under reduced pressure, and use preparative liquid chromatography to purify and separate the compounds:

[0113] R1-7 (19.6 mg), LC-MS: 804.4 (M / 2 + 1), 536.6 (M / 3 + 1)

[0114] R1-8 (0.1 mg), LC-MS: 808.4 (M / 3 + 1), 606.5 (M / 4 + 1)

[0115] R1-9 (0.1 mg), LC-MS: 808.4 (M / 3 + 1), 606.5 (M / 4 + 1)

[0116] R1-10 (29.6 mg), LC-MS: 808.4 (M / 3 + 1), 606.5 (M / 4 + 1)

[0117] R1-11 (34.4 mg), LC-MS: 810.1 (M / 4 + 1), 648.3 (M / 5 + 1) R1-12 (39.1 mg), LC-MS: 676.3 (M / 6 + 1)

[0118]

[0119]

[0120]

[0121] Example 4

[0122] In this example, we prepared compounds R1-13, R1-14, R1-15, R1-16, R1-17, and R1-18 by coupling compound R1 with compound Y.

[0123]

[0124] Dissolve compound 4 (79.2 mg, 0.1 mmol), N,N-diisopropylethylamine (64.5 mg, 0.5 mmol) and HATU (114 mg, 0.3 mmol) in 2 ml of DMF solution. After stirring for 10 min, add compound Y (196.5 mg, 0.3 mmol). After reacting for 2 h, concentrate the reaction solution under reduced pressure, and use preparative liquid chromatography to purify and isolate compound R1-13 (13.9 mg). LC-MS: 715.8 (M / 2 + 1), 477.6 (M / 3 + 1)

[0125] R1-14 (0.1 mg), LC-MS: 690.3 (M / 3 + 1), 517.9 (M / 4 + 1)

[0126] R1-15 (0.2 mg), LC-MS: 690.3 (M / 3 + 1), 517.9 (M / 4 + 1)

[0127] R1-16 (19.8 mg), LC-MS: 690.3 (M / 3 + 1), 517.9 (M / 4 + 1)

[0128] R1-17 (22.8 mg), LC-MS: 677.3 (M / 4 + 1)

[0129] R1-18 (21.5 mg), LC-MS: 836.7 (M / 4 + 1), 669.6 (M / 5 + 1)

[0130]

[0131]

[0132] Example 5

[0133]

[0134] Dissolve 2,6-diformyl-4-methylphenol (0.82 g, 5 mmol) in 300 ml of methanol, and dropwise add a 300 ml methanol solution of bis(3-aminopropyl) ether (0.66 g, 5 mmol). After dropping, continue the reaction for 2 hours. Then add sodium borohydride (760 mg, 20 mmol) in batches. After reacting for 1 h, concentrate and purify to obtain compound 5 (1.01 g). LC-MS: 529.4 (M + 1)

[0135] H-NMR (300M, D2O): δ 1.95 - 2.01 (m, 8H), 2.28 (s, 6H), 3.14 - 3.17 (t, 8H), 3.60 - 3.63 (t, 8H), 4.24 (s, 8H), 7.24 (s, 4H)

[0136] Compound 5 (528 mg, 1 mmol), tert-butyl bromoacetate (1.17 g, 6 mmol), DIEA (1.03 g, 8 mmol) and 30 ml of acetonitrile were mixed and reacted at room temperature for 2 hours. Concentrated to dryness, extracted with ethyl acetate / water, dried and concentrated to obtain the crude product, which was purified to obtain Compound 6 (804 mg).

[0137] Compound 6 (328 mg, 0.33 mmol) was dissolved in 4M hydrochloric acid (3 ml) and reacted at 45 °C for 0.5 hour. Concentrated under reduced pressure to dryness, and purified by preparation to obtain the target compound R2 (124 mg).

[0138] LC-MS: 761.4 (M+1), 381.3 (M / 2+1)

[0139] H-NMR (300M, D2O): δ 2.11 (br, 8H), 2.28 (s, 6H), 3.45 (br, 8H), 3.55 (br, 8H), 3.90 (br, 8H), 4.52 (br, 8H), 7.26 (s, 4H)

[0140] Example 6

[0141] In the same manner as in Example 5, only bis(3-aminopropyl) ether was replaced with 2,2'-oxybis(ethylamine) to obtain Compound R3.

[0142]

[0143] Among them:

[0144] Compound 8:

[0145] LC-MS: 473.3 (M+1)

[0146] H-NMR (300M, D2O): δ 2.28 (s, 6H), 3.25 - 3.28 (t, 8H), 3.70 - 3.73 (t, 8H), 4.25 (s, 8H), 7.24 (s, 4H).

[0147] Compound R3:

[0148] LC-MS: 705.3 (M+1), 353.2 (M / 2+1)

[0149] H-NMR (300M, D2O): δ 2.28 (s, 6H), 3.49 (br, 8H), 3.56 (br, 8H), 3.90 (br, 8H), 4.52 (br, 8H), 7.26 (s, 4H).

[0150] Example 7

[0151] In the same manner as in Example 5, only bis(3-aminopropyl) ether was replaced with diethylenetriamine to obtain compound R4.

[0152]

[0153] Wherein:

[0154] Compound 11:

[0155] LC-MS: 471.3 (M+1)

[0156] H-NMR (300M, D2O): δ 2.28 (s, 6H), 3.33 - 3.36 (m, 8H), 3.42 - 3.46 (m, 8H), 4.34 (s, 8H), 7.30 (s, 4H), see specifically Figure 5 .

[0157] Compound R4:

[0158] LC-MS: 819.4 (M+1), 352.2 (M / 2+1)

[0159] H-NMR (300M, D2O): δ 2.28 (s, 6H), 3.14 (m, 8H), 3.30 (m, 4H), 3.43 (m, 8H), 3.90 (s, 8H), 4.46 (s, 8H), 7.33 (s, 4H), see specifically Figure 6 .

[0160] Example 8

[0161] In the same manner as in Example 5, only bis(3-aminopropyl) ether was replaced with aminoethyl sulfide to obtain compound R5.

[0162]

[0163] Wherein:

[0164] Compound R5:

[0165] LC-MS: 737.3 (M+1), 369.1 (M / 2+1)

[0166] H-NMR (300M, D2O): δ 2.28 (s, 6H), 2.58 (br, 8H), 3.41 (br, 8H), 3.90 (br, 8H), 4.52 (br, 8H), 7.26 (s, 4H)

[0167] Example 9

[0168]

[0169] 70.6 mg (0.1 mmol) of Intermediate 2 was added to 2 ml of acetonitrile, followed by the addition of DIEA (1.29 g, 10 mmol). While stirring, 176 mg (0.6 mmol) of Compound V was added. After reacting for 6 hours, the crude product of Compound 17 was obtained after work-up and purified to give 119 mg.

[0170] LC-MS: 707.3 (M / 2 + 1)

[0171] 50 mg of Compound 17 was dissolved in 1 ml of a mixture of acetic acid / concentrated hydrochloric acid (1:1) and reacted at 55 °C for 6 hours. After concentration, Compound R6 was obtained after purification.

[0172] Compound R6:

[0173] LC-MS: 527.4 (M / 2 + 1)

[0174] H-NMR (300M, D2O): δ 2.14 (s, 6H), 3.66 (s, 6H), 3.78 (s, 6H), 3.99 (s, 6H), 4.56 (s, 6H), 6.60 - 6.62 (d, 4H), 6.70 - 6.71 (d, 4H), 7.10 (s, 4H), 7.43 - 7.47 (t, 4H), specifically refer to Figure 7 .

[0175] Example 10

[0176]

[0177] Referring to Example 9, Compound V was replaced with Compound VI to obtain Compound R7

[0178] Compound 19:

[0179] LC-MS: 635.3 (M / 2 + 1)

[0180] H-NMR (300M, D2O): δ 2.33 (s, 6H), 3.11 - 3.19 (m, 20H), 3.66 - 3.78 (m, 24H), 4.24 (s, 8H), 4.91 (s, 8H), 7.25 (s, 4H), 7.41 - 7.45 (m, 20H) Compound R7:

[0181] LC-MS: 455.2 (M / 2 + 1)

[0182] Example 11

[0183]

[0184] Refer to Example 9, replace Compound V with Compound VII to obtain Compound R8

[0185] Compound R8:

[0186] LC-MS: 469.2 (M / 2 + 1)

[0187] Example 12

[0188]

[0189] Refer to Example 9, replace Compound V with Compound VIII to obtain Compound R9

[0190] Compound R9:

[0191] LC-MS: 699.2 (M / 2 + 1)

[0192] Example 13

[0193]

[0194] 1,7-bis-BOC-1,4,7-triazaheptane (303 mg, 1 mmol) was dissolved in acetonitrile, DIEA (129 mg, 1 mmol) and tert-butyl bromoacetate (195 mg, 1 mmol) were added, and the mixture was stirred and reacted for 2 hours. After extraction and washing, the crude product was purified by column chromatography to obtain Compound 25 (358 mg).

[0195] LC-MS: 474.2 (M + 23), 396.2 (M + 1 - 56)

[0196] Compound 25 (225 mg, 0.5 mmol) was dissolved in 20 ml of dichloromethane, 1 M hydrogen chloride dioxane solution (1 ml) was added dropwise, after 30 minutes, it was diluted with 20 ml of dichloromethane, and concentrated to obtain 163 mg of the hydrochloride salt of Compound 26 as the crude product. LC-MS: 252.2 (M + 1)

[0197] 2,6-Diformyl-4-methylphenol (74 mg, 0.45 mmol) was dissolved in 30 ml of methanol and heated to 60 °C. A 20 ml methanol solution of Compound 26 (163 mg, 0.5 mmol) was added dropwise, and after dropping, the reaction was continued for 2 hours.

[0198] After reaching 45 °C, sodium borohydride (76 mg, 2 mmol) was added to the reaction solution with stirring, and the reaction was stirred for 1 hour. The solvent was removed under reduced pressure, and the residue was extracted and washed to obtain the crude product of compound 27 (79 mg).

[0199] LC-MS: 384.2 (M / 2 + 1)

[0200] The crude product of compound 27 (79 mg, 0.1 mmol) was added to DMF, and DIEA (88 mg, 0.68 mmol) and compound V (199 mg, 0.68 mmol) were added with stirring. The reaction was stirred overnight. Ethyl acetate and water were added, and the mixture was extracted and washed to obtain 126 mg of the crude product, which was purified to obtain 81 mg of compound 28

[0201] LC-MS: 540.8 (M / 3 + 1)

[0202] Compound 28 (81 mg) was added to 2 ml of concentrated hydrochloric acid, and the reaction was carried out at 55 °C for 30 minutes. The mixture was concentrated to dryness and purified by preparation to obtain compound R10

[0203] LC-MS: 540.2 (M / 2 + 1)

[0204] The present invention provides a chelating ligand compound, which has a ligand skeleton friendly to radionuclides with large atomic radii, so that heating is not required during chelation with radioactive metal nuclides, and the coordination effect during chelation is strong, the formed metal complex has high stability, and the radioactive metal nuclide is not likely to escape; at the same time, the present invention uses different functional groups capable of binding to the target molecule to substitute carboxyl groups with different numbers and at different positions, forming chelating ligand compounds with different numbers and at different positions, which can improve the binding sites and ability with the target molecule when binding to the target molecule. In summary, the chelating ligand compounds disclosed in the present invention, as well as the compounds formed by binding the chelating ligand compounds with the target molecule and / or the complexes formed by complexing with metal nuclides, have better targeting and stability when used as imaging agents for diagnosis or for exerting therapeutic effects using α and β rays generated by nuclides.

[0205] Next, we will further illustrate by combining the preparation examples of markers and the in vivo PET imaging experiment examples.

[0206] Example 14

[0207] The Ge-Ga generator was eluted with a hydrochloric acid solution with a concentration of 0.1 M to obtain a radioactive nuclide-containing 68 Ga 3+eluent; add 1M sodium acetate solution to the eluent to adjust the pH value of the eluent to 4.0; add 20nM chelating ligand compound R1 to the eluent, shake well and react at room temperature for 10 minutes to obtain a radioactive nuclide Ga-68 labeled compound 68 Ga-R1.

[0208] Detection of compounds by instant thin layer chromatography 68 Ga-R1 radiochemical purity. Instant thin layer chromatography detection conditions are: iTLC-SG chromatography plate; methanol / 1M ammonium acetate = 1 / 1 (v / v) developing solvent, the results are as follows Figure 8 As shown in the figure, it can be seen that the reaction solution 68 The Ga-R1 product accounted for 95.9% of the total activity of the reaction solution, indicating that the chelating ligand compound R1 can be efficiently labeled at room temperature.

[0209] According to the above method, the chelating ligand compound R2, the compound R3, and the compound 28 are respectively mixed with the radioactive nuclide 68 Ga 3+ Radiolabeling was performed in a Ge-Ga generator to obtain compounds labeled with the radionuclide Ga-68 68 Ga-R2, compounds 68 Ga-R3.

[0210] Then, the compounds were determined by instant thin layer chromatography. 68 Ga-R2, compounds 68 The radiochemical purity of Ga-R3 is as follows Figure 9 and Figure 10 As shown, according to the results shown in the figure, it can be seen that the chelating ligand compound R2, compound R3 and compound 28 can all be efficiently labeled at room temperature.

[0211] According to the above method, the chelating ligand compound R4, the compound R5, and the compound R6 are respectively 68 Ga 3+ Radiolabeling was performed in a Ge-Ga generator to obtain compounds labeled with the radionuclide Ga-68 68 Ga-R4, compound 68 Ga-R5 and compounds 68 Ga-R6.

[0212] Then, the compounds were determined by instant thin layer chromatography. 68 Ga-R4, compound 68 Ga-R5 and compounds 68 The radiochemical purity of Ga-R6 is as follows Figures 11 - 13As shown, according to the illustrated results, it can be seen that the chelating ligand compounds R4, compound R5, and compound R6 can all be efficiently labeled at room temperature.

[0213] All the compounds disclosed in the present invention can react with 68 radionuclides such as Ga at room temperature with high efficiency, which will not be listed one by one here.

[0214] Example 15

[0215] Below, we will take the coupling of compound R1 and compound W to prepare compound R1-4 as an example to illustrate the labeling of radionuclides in the compounds with macrocyclic coupling targeting structures.

[0216] Wash the Ge-Ga generator with a hydrochloric acid solution with a concentration of 0.1 M to obtain an eluate containing the radionuclide 68 Ga 3+ ; add a sodium acetate solution with a concentration of 1 M to the eluate to adjust the pH value of the eluate to 4.2; add 20 μM of compound R1-4 to the eluate, shake well, and react at room temperature for 10 min. Add 5 mL of water to the reaction solution for dilution, and then purify it using an Oasis HLB solid-phase extraction cartridge. After loading, washing with water, and eluting with an ethanol solution with a concentration of 50%, the product, the labeled compound 68 Ga-R1-4 is obtained.

[0217] Analyze the product using high-performance liquid chromatography with a radioactive detector. The analysis conditions for high-performance liquid chromatography are as follows: Phenomenex Luna C18(2) chromatographic column (5 μ, 150×4.60 mm); flow rate 1 mL / min; gradient elution, from 0 to 3 minutes, acetonitrile is 10% and trifluoroacetic acid solution (0.1%) is 90%, from 3 to 10 minutes, acetonitrile changes from 10% to 70% and trifluoroacetic acid solution changes from 90% to 30%, from 10 to 12 minutes, acetonitrile changes from 70% to 10% and trifluoroacetic acid solution changes from 30% to 90%, and from 12 to 15 minutes, acetonitrile remains 10% and trifluoroacetic acid solution remains 90%. The results are as Figure 14 shown, and it can be seen that 68 the retention time of Ga-R1-4 is 7.88 minutes, and the results show that the radiochemical purity of the product is 97%.

[0218] According to the aforementioned method, use 68 Ga 3+ to label compound R1-5, compound R1-6, compound R1-7, compound R1-10, compound R1-11, and compound R1-12 respectively, and obtain the labeled compounds 68 Ga-R1-5, 68 Ga-R1-6, 68 Ga-R1-7,68 Ga-R1-10, 68 Ga-R1-11, 68 Ga-R1-12.

[0219] Each labeled compound was analyzed by high performance liquid chromatography with a radioactive detector, and the experimental results are as Figures 15 - 20 shown.

[0220] It can be seen that the radiochemical purity of the labeled product is high.

[0221] From the above examples of radionuclide labeling, it can be seen that the structure of the macrocyclic conjugate targeting compound disclosed in the present invention can be efficiently labeled at room temperature, and the obtained product has high radiochemical purity.

[0222] Each compound disclosed in the present invention can be efficiently labeled with 68 radionuclides such as Ga, and will not be listed one by one here.

[0223] Example 16

[0224] Separate the labeled macrocyclic conjugate targeting compounds 68 Ga-R1-4, 68 Ga-R1-6, 68 Ga-R1-12 were used for PET imaging experiments.

[0225] 200 μC of the radiochemically labeled compound 68 Ga-R1-4 was injected into a nude mouse model bearing U87MG tumors via the tail vein. PET image data was collected for 10 minutes 60 minutes after injection. The results are as Figure 21 shown, indicating that the compound 68 Ga-9 had significant uptake and retention in U87MG tumor tissue (the position indicated by the arrow in the figure).

[0226] According to the above method, 200 μC of the radiochemically labeled compound 68 Ga-R1-6 and the compound 68 Ga-R1-12 were respectively injected into a nude mouse model bearing U87MG tumors via the tail vein, and the Figure 22 and Figure 23 shown PET imaging diagrams were obtained. It can be seen that the radiochemically labeled compounds 68 Ga-R1-6 and the compound 68 Ga-R1-12 had significant uptake and retention in U87MG tumor tissue (the position indicated by the arrow in the figure).

[0227] Example 17

[0228] Next, we use 68Taking Ga-R1-4 as an example, the pharmacokinetic data of the compounds obtained by the present invention in animals are described.

[0229] Nine U87gm tumor-bearing nude mouse models were taken and randomly divided into 3 groups with 3 mice in each group. 50 μCi 68 Ga-R1-4 was injected into the tumor-bearing mice through the tail vein. Then, the nude mice were sacrificed at 30, 60, and 120 minutes after injection, the organs were separated, weighed, and the radioactivity counts in each organ were measured, and the radioactivity uptake values in the tissue per unit mass were calculated. 68 The distribution results of Ga-R1-4 in the tumor-bearing mice are as Figure 24 shown, indicating that the tracer has a high uptake and retention in the tumor, while less uptake in non-tumor tissues, and the uptake of the drug in the tumor is continuously increasing, while it is gradually metabolized in other non-tumor tissues, showing a decreasing trend.

[0230] The above are the specific embodiments of the present invention. It should be noted that for those of ordinary skill in the art, without departing from the principle of the present invention, several improvements and refinements can be made, and these improvements and refinements are also regarded as the protection scope of the present invention.

Claims

1. A chelating ligand compound, characterized in that, The chelating ligand compound includes a chelating group containing multiple nitrogen atoms and at least one linking arm connected to the nitrogen atom on the chelating group: Wherein: Z is a chelating group containing multiple nitrogen atoms and has the following structure: R1 and R2 are substituents on the benzene ring, and the substituent does not contain a residue reactive with the target molecule; further preferably, R1 = R2; more preferably, both R1 and R2 are methyl groups; K is an alkyl chain containing a heteroatom O, S, P or N, which is formed by connecting several Rs k through a heteroatom or a heteroatom-containing group, where R k is independently and optionally selected from substituted or unsubstituted alkyl; L is a linking arm portion connected to the N atom in the chelating group Z, and the linking arm portion L has a terminal group X connected to the target molecule or the targeting group.

2. The chelating ligand compound according to claim 1, characterized in that: The chelating ligand compound further includes a group Q, and the group Q is a heteroatom group with a lone pair of electrons; There are two ways for the group Q to be connected to the chelating group Z, One is that the group Q is connected between the chelating group Z and the linking arm portion L, The other is that the group Q is directly connected to the N atoms in the chelating group Z that are not connected to the linking arm portion L, 3. The chelating ligand compound according to claim 1, wherein: The linking arm portion L is selected from groups having the following formula: L m -X, Wherein: X is —COOH, —OH, —CO, —SH, —CO—N(CH3)OH, —NH2, —H2PO3, —H2PO4, —H2PO2 or a halogen; L m is a substituted or unsubstituted alkyl group, preferably, L m is a substituted or unsubstituted C0-C3 alkyl group.

4. The chelating ligand compound according to claim 1, characterized in that, R k selected from substituted or unsubstituted methyl, substituted or unsubstituted ethyl, and substituted or unsubstituted propyl.

5. The chelating ligand compound according to claim 1, characterized in that, The chelating ligand compound also has any of the following preferences, (1) The alkyl chain K containing heteroatoms O, S, P or N is selected from: Any one of them; (2) The group Q is selected from groups having the following formula, Q m -X Q ; Wherein: Q m is a substituted or unsubstituted alkyl group. Preferably, Q m is a substituted or unsubstituted C0-C3 alkyl group; X Q is a heteroatom group with lone pair electrons, including but not limited to —COOH, —H2PO3, —H2PO4 or —H2PO2; (3) The chelating ligand compound is arbitrarily selected from:

6. The derivative of the chelating ligand as described in claim 1, characterized in that, The derivative is a compound having the structure shown by the following formula or a salt formed by it with an inorganic acid or an organic acid, 7. A conjugate formed by coupling the chelating ligand compound according to any one of claims 1 to 5 with a target molecule or a targeting group.

8. The preparation method of the chelating ligand compound according to claim 1, characterized in that, This method is prepared from substituted or unsubstituted 2,6-diformylphenol dissolved in NH2—K—NH2, wherein the definition of K is as described in any one of claims 1-5.

9. A metal complex formed by the chelating ligand compound according to any one of claims 1 to 5 or the conjugate according to claim 7.

10. Use of the chelating ligand compound according to any one of claims 1 to 5, the derivative according to claim 6, the conjugate according to claim 7, and the metal complex according to claim 9 in the preparation of radiopharmaceuticals.